UAB "CAERUS BIOTECHNOLOGIES" – Trademark Portfolio

Entity Type: 03

UAB "CAERUS BIOTECHNOLOGIES" holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 1 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include MIOXSYS. The owner is based in VILNIUS.

VILNIUS LT-04326 , LT

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

MIOXSYS
MIOXSYS
Registered 2015

Trademark Classifications

UAB "CAERUS BIOTECHNOLOGIES"'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (1 filing)

Surgical, medical, dental and veterinary apparatus and instruments

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does UAB "CAERUS BIOTECHNOLOGIES" have?

UAB "CAERUS BIOTECHNOLOGIES" has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does UAB "CAERUS BIOTECHNOLOGIES" file in?

UAB "CAERUS BIOTECHNOLOGIES" files trademarks across 2 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 5 (Pharmaceuticals). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are UAB "CAERUS BIOTECHNOLOGIES"'s most well-known trademarks?

UAB "CAERUS BIOTECHNOLOGIES"'s registered trademark portfolio includes well-known marks such as MIOXSYS. These are among 1 currently registered trademark in the portfolio.

What is UAB "CAERUS BIOTECHNOLOGIES"'s trademark registration success rate?

UAB "CAERUS BIOTECHNOLOGIES" has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.